VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

Dengue DNA Vaccine encoding NS1 Protein
Vaccine Information
  • Vaccine Name: Dengue DNA Vaccine encoding NS1 Protein
  • Target Pathogen: Dengue Virus
  • Target Disease: Dengue Fever
  • Vaccine Ontology ID: VO_0011454
  • Type: DNA vaccine
  • Status: Research
  • NS1 gene engineering:
    • Type: DNA vaccine construction
    • Description:
    • Detailed Gene Information: Click Here.
  • DNA vaccine plasmid:
    • DNA vaccine plasmid name:
    • DNA vaccine plasmid VO ID: VO_0000132
  • Immunization Route: Intramuscular injection (i.m.)
Host Response

Mouse Response

  • Host Strain: C57/BL6, Balb/c, and C3H
  • Vaccination Protocol: Groups of 3–4 weeks old female C3H mice were initially immunized with 80 μg of recombinant DNA pD2NS1, or pcDNA3 as a control. Recombinant pD2NS1 in PBS, control pcDNA3 in PBS, or PBS buffer alone was intramuscularly (i.m.) injected into the mouse thighs; the mice were subsequently boosted twice using the same method at 1 week interval (Wu et al., 2003).
  • Challenge Protocol: One week after the final boost, mice were i.v. challenged with 5×10^6 plaque-forming units of PL046 in 100 μl PBS. The mice after virus challenge were monitored daily for morbidity and mortality for weeks (Wu et al., 2003).
  • Efficacy: Intravenously challenged by lethal DEN-2, mice vaccinated with NS1-DNA exhibited a delay onset of paralysis, a marked decrease of morbidity, and a significant enhancement of survival (Wu et al., 2003).
References
Wu et al., 2003: Wu SF, Liao CL, Lin YL, Yeh CT, Chen LK, Huang YF, Chou HY, Huang JL, Shaio MF, Sytwu HK. Evaluation of protective efficacy and immune mechanisms of using a non-structural protein NS1 in DNA vaccine against dengue 2 virus in mice. Vaccine. 2003; 21(25-26); 3919-3929. [PubMed: 12922127].